Comparing Weight Loss/Rebound between Distinct CB1 Inhibitors

Preclinical data assesses weight loss and rebound of peripheral CB1-inhibiting antibody, nimacimab, versus small molecule CB1 inhibitor, monlunabant.

Released September 4, 2025

Assessing Additive Effects when Combined with Tirzepatide

Data highlighting combination of nimacimab and suboptimal tirzepatide versus either drug alone in terms of weight loss, rebound and maintenance.

Released September 4, 2025

Assessing Nimacimab + Incretin Combination Weight Loss Dynamics

This research showed that nimacimab-driven weight loss is not a result of caloric deficit alone (via pair-fed study), as well as incremental weight rebound and maintenance benefits.

Released September 4, 2025

A Look at Manufacturing Nimacimab

Skye's COO discusses FDA requirements and considerations around manufacturing a monoclonal antibody such as nimacimab.

Released September 1, 2025

Nimacimab Promotes Metabolic Homeostasis

ADA poster highlights nimacimab’s weight loss and metabolic improvements including enhanced body composition, metabolic restoration, and improved hormonal profile in diet-induced obesity model.

Released June 23, 2025

Diet-induced Obesity Model Weight Loss and Biomarker Data

Obesity conference presentation notes nimacimab’s differentiation, weight loss data from preclinical obesity model, and new biomarker data showing reduction in obesity-induced inflammation and liver steatosis.

Released June 22, 2025

Revisiting the Potential Role of a Restricted CB1 Inhibitor

This update highlights Skye’s progress in obesity drug development, noting the differentiation of its allosteric modulating antibody that takes into consideration fat metabolism, safety and long-term care.

Released June 20, 2025

Nimacimab: Designed to Offer Distinct Capabilities

This article characterizes Skye’s highly peripherally-restricted CB1 inhibitor and its advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data.

Released June 20, 2025

Assessing the Effect of Nimacimab’s Mechanistic Differences

CB1 inhibition offers the prospect of modulating mechanisms complementarily to incretins. Skye's CBeyond Phase2a trial is assessing its CB1 inhibitor's weight loss effects in monotherapy and combination arms.

Released June 20, 2025